Unveiling the Therapeutic Potential of Quinazolinone Derivatives in Cancer Treatment: A Comprehensive Exploration
ChemistrySelect · 27.08.2024 · 9 (32)
DOI: 10.1002/slct.202401366 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 22.08.2024. Verfasst von Jasneet Kaur und 5 weiteren Autor:innen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 102 Literaturangaben.
Abstract (Originalsprache)
Quinazolinone derivatives have garnered attention for their diverse biological activities, including anticancer properties. This review combines findings from 2018 to 2024, focusing on the impact of quinazolinones on cancer cells, tubulin formation, and EGFR/PI3 K pathways. By unraveling the intricacies of structure‐activity relationships, this review endeavors to provide guidance for researchers in identifying promising avenues for the development of cancer treatments. Although in vitro studies underscore significant potential, it is imperative that future research prioritizes pre‐clinical investigations to seamlessly traverse the transitional phase towards clinical applications, thereby propelling the advancement of quinazolinone‐based cancer therapy.
Zitieren
APA
Kaur, J., Kaur, S., Muskan, Kaur, N., Kumar, V., & Anand, A. (2024). Unveiling the Therapeutic Potential of Quinazolinone Derivatives in Cancer Treatment: A Comprehensive Exploration. ChemistrySelect, 9(32). https://doi.org/10.1002/slct.202401366
Vancouver
Kaur J, Kaur S, Muskan, Kaur N, Kumar V, Anand A. Unveiling the Therapeutic Potential of Quinazolinone Derivatives in Cancer Treatment: A Comprehensive Exploration. ChemistrySelect. 2024;9(32). doi:10.1002/slct.202401366
BibTeX
@article{Kaur2024,
author = {Kaur, Jasneet and Kaur, Sukhmeet and Muskan and Kaur, Navneet and Kumar, Vipan and Anand, Amit},
title = {Unveiling the Therapeutic Potential of Quinazolinone Derivatives in Cancer Treatment: A Comprehensive Exploration},
journal = {ChemistrySelect},
year = {2024},
volume = {9},
number = {32},
doi = {10.1002/slct.202401366}
}
EUVIMED